Top

Gepubliceerd in:

03-08-2024 | Review

The impact of dipeptidyl peptidase 4 inhibitors on health-related quality of life in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Auteurs: Xinyue Zhang, Wai Kei Tong, Qian Xia, Zhijia Tang

Gepubliceerd in: Quality of Life Research | Uitgave 12/2024

Abstract

Purpose

To evaluate the impact of dipeptidyl peptidase 4 (DPP-4) inhibitors on Health-related quality of life (HRQOL) in patients with type 2 diabetes mellitus (T2DM) compared with other hypoglycemic agents.

Methods

A systematic review and meta-analysis based on randomized controlled trials was conducted following the Cochrane Handbook and PRISMA. Studies were identified by searching PubMed (MEDLINE), EMBASE, Web of Science, CNKI, WANGFANG DATA, VIP DATABASE, Google Scholar, and Cochrane Central Register of Controlled Trials from database inception to Dec 30, 2023. The main result was HRQOL scores. The outcomes were extracted using the mean difference (MD) from each study. Sensitivity analysis and subgroup analysis were also performed.

Results

Forty studies (4,579 participants) were included, with 32 pooled for meta-analysis. DPP-4 inhibitors alongside conventional treatment significantly enhanced HRQOL compared to conventional treatment alone (MD = 9.85, 95% CI [7.98–11.71], P < 0.001; heterogeneity, I² = 94%, P < 0.001), as assessed by SF-36 using a random-effects model. No additional benefit was found when measured by DTR-QOL using a fixed-effects model (MD = 2.29, 95% CI [-0.06-4.64], P = 0.06; heterogeneity, I² = 49%, P = 0.1) and compared to SGLT-2 inhibitors. Subgroup analysis indicated that DPP-4 inhibitors favored patients ≥ 60 years old on medication for ≥ 6 months.

Conclusions

DPP-4 inhibitors were superior for T2DM HRQOL improvement. More long-term, multicenter evidence is needed to generalize findings and compare them with newer hypoglycemic agents.

Systematic review registration

PROSPERO: CRD42023440134.

volgende artikel Twenty-five years of experience with patient-reported outcome measures in soft-tissue sarcoma patients: a systematic review

International Diabetes Federation. Accessed June, 24 (2023). https://diabetesatlas.org/

Maranta, F., Cianfanelli, L., & Cianflone, D. (2020). Glycaemic Control and Vascular complications in Diabetes Mellitus Type 2. Advances in Experimental Medicine and Biology, 129–152. https://doi.org/10.1007/5584_2020_514

Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia Dec, 61(12), 2461–2498. https://doi.org/10.1007/s00125-018-4729-5CrossRef

The World Health Organization Quality of Life Assessment (WHOQOL). (1998). Development and general psychometric properties. Soc Sci Med Jun, 46(12), 1569–1585. https://doi.org/10.1016/s0277-9536(98)00009-4CrossRef

Centers for Disease Control and Prevention Measuring healthy days: Population assessment of health-related quality of life. https://www.cdc.gov/hrqol/pdfs/mhd.pdf

Mills, S., Torrance, N., & Smith, B. H. (2016). Identification and Management of Chronic Pain in Primary Care: A review. Curr Psychiatry Rep Feb, 18(2), 22. https://doi.org/10.1007/s11920-015-0659-9CrossRef

Jain, V., Shivkumar, S., & Gupta, O. (2014). Health-related quality of life (hr-qol) in patients with type 2 diabetes mellitus. N Am J Med Sci Feb, 6(2), 96–101. https://doi.org/10.4103/1947-2714.127752CrossRef

Royall, D. R., Chiodo, L. K., & Polk, M. J. (2005). An empiric approach to level of care determinations: The importance of executive measures. J Gerontol A Biol Sci Med Sci Aug, 60(8), 1059–1064. https://doi.org/10.1093/gerona/60.8.1059CrossRef

Aguiar, C. C., Vieira, A. P., Carvalho, A. F., & Montenegro-Junior, R. M. (2008). Assessment instruments for a health-related quality of life in diabetes mellitus. Arq Bras Endocrinol Metabol Aug, 52(6), 931–939. https://doi.org/10.1590/s0004-27302008000600004. Instrumentos de avaliação de qualidade de vida relacionada à saúde no diabetes melito.CrossRef

10.

Ishii, H. (2012). Development and psychometric validation of the diabetes therapy-related QOL (DTR-QOL) questionnaire. Journal of Medical Economics, 15(3), 556–563. https://doi.org/10.3111/13696998.2012.665111CrossRefPubMed

11.

Wang, L. S., Sun, Z. Q., Cai, T. S., & Zhou, Z. G. (2005). Development and evaluation of quality of life scale for patients with type 2 diabetes mellitus. Zhong Nan Da Xue Xue Bao Yi Xue Ban Feb, 30(1), 21–27.

12.

Farah, D., Leme, G. M., Eliaschewitz, F. G., & Fonseca, M. C. M. (2019). A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis. Diabetes Res Clin Pract Mar, 149, 47–63. https://doi.org/10.1016/j.diabres.2019.01.025CrossRef

13.

Stoian, A. P., Sachinidis, A., Stoica, R. A., Nikolic, D., Patti, A. M., & Rizvi, A. A. (2020). The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism Aug, 109, 154295. https://doi.org/10.1016/j.metabol.2020.154295CrossRef

14.

Gallwitz, B. (2019). Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne), 10, 389. https://doi.org/10.3389/fendo.2019.00389CrossRefPubMed

15.

Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. L. (2008). Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev Apr, 16(2), Cd006739. https://doi.org/10.1002/14651858.CD006739.pub2CrossRef

16.

McIntosh, B., Cameron, C., Singh, S. R., Yu, C., Ahuja, T., Welton, N. J., & Dahl, M. (2011). Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A systematic review and mixed-treatment comparison meta-analysis. Open Medicine, 5(1), e35–48.PubMedPubMedCentral

17.

Goto, H., Mita, T., Fujitani, Y., Fujimoto, S., Takahashi, K., Satoh, H., Hirose, T., Hiyoshi, T., Ai, M., Okada, Y., Nishimura, H., Kuroda, H., Matsubara, T., Gosho, M., Ishii, H., & Watada, H. (2018). Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: Sub-analysis of the L-STEP study. Endocr J Jun, 27(6), 657–668. https://doi.org/10.1507/endocrj.EJ18-0088CrossRef

18.

Katsuno, T., Shiraiwa, T., Iwasaki, S., Park, H., Watanabe, N., Kaneko, S., Terasaki, J., Hanafusa, T., Imagawa, A., Shimomura, I., Ikegami, H., Koyama, H., Namba, M., & Miyagawa, J. I. (2020). Benefit of Early add-on of Linagliptin to insulin in Japanese patients with type 2 diabetes Mellitus: Randomized-controlled open-label trial (TRUST2). Adv Ther Mar, 38(3), 1514–1535. https://doi.org/10.1007/s12325-021-01631-yCrossRef

19.

Mita, T., Hiyoshi, T., Yoshii, H., Chimori, H., Ikeda, K., Shimizu, M., Kojima, Y., Yamamto, H., Yasuda, D., Sato, J., & Watada, H. (2019). The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in patients with type 2 diabetes Mellitus. Diabetes Ther Feb, 10(1), 119–134. https://doi.org/10.1007/s13300-018-0539-5CrossRef

20.

Ishii, H., Nakajima, H., Kamei, N., Niiya, T., Hiyoshi, T., Hiramori, Y., Ohtsu, S., Noto, T., & Shimono, D. (2020). Quality-of-life comparison of Dapagliflozin Versus Dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes Mellitus: A randomized controlled trial (J-BOND study). Diabetes Ther Dec, 11(12), 2959–2977. https://doi.org/10.1007/s13300-020-00941-8CrossRef

21.

Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & VA W. (2022). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). https://training.cochrane.org/handbook

22.

Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hrobjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., et al. (2021). PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ Mar, 29, 372:n160. https://doi.org/10.1136/bmj.n160CrossRef

23.

Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H. Y., Corbett, M. S., Eldridge, S. M., Emberson, J. R., Hernán, M. A., Hopewell, S., Hróbjartsson, A., Junqueira, D. R., Jüni, P., Kirkham, J. J., Lasserson, T., Li, T., et al. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. Bmj Aug, 28, 366:l4898. https://doi.org/10.1136/bmj.l4898CrossRef

24.

Sterne, J. A., Sutton, A. J., Ioannidis, J. P., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rücker, G., Harbord, R. M., Schmid, C. H., Tetzlaff, J., Deeks, J. J., Peters, J., Macaskill, P., Schwarzer, G., Duval, S., Altman, D. G., Moher, D., & Higgins, J. P. (2011). Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Bmj Jul, 22, 343:d4002. https://doi.org/10.1136/bmj.d4002CrossRef

25.

Xingbing, C., & Defa, Z. (2020). Clinical observation of Sitagliptin phosphate combined with metformin in treatment of patients with incipient type 2 diabetes. Healthmust-Readmagazine, 8, 26.

26.

Hua, C. (2019). Effects of dipeptidyl peptidase-4 inhibitors combined with real-time dynamic insulin pumps on blood glucose control and quality of life in newly diagnosed type 2 diabetes patients. HENAN MEDICAL RESERACH, 28(20), 3729–3731.

27.

Ruihua, G. (2019). Efficacy of sitagliptin combined with protamine biosynthetic human insulin injection (30R) in the treatment of elderly patients with type 2 diabetes mellitus. HENAN MEDICAL RESERACH, 28(9), 1636–1637.

28.

Yuming, H. (2021). Clinical observation of Vigliptin combined with insulin intensive therapy in newly diagnosed T2DM patients. Public Medical Forum Magazine, 25(13), 1856–1858. https://doi.org/10.19435/j.1672-1721.2021.13.038CrossRef

29.

Dengling, A. J. (2017). Effects of insulin aspartate 30 injection combined with Vigliptin on blood glucose control and quality of life in patients with type 2 diabetes mellitus. Capital Food and Medicine, 25(13), 44. https://doi.org/10.3969/j.issn.1005-8257.2018.13.038CrossRef

30.

Yongjun, J. (2018). Effect of saxagliptin combined with early intensive insulin pump on blood glucose level and SF-36 score in newly diagnosed patients with type 2 diabetes. Journal of Practical Diabetology, 15(6), 31–32.

31.

Lu, L., & Haiyan, W. (2020). Effect of Vigliptin combined with insulin intensive therapy on blood glucose control and health survey summary score in newly diagnosed type 2 diabetes patients. Shanxi Medicine Journal, 49(5), 571–573. https://doi.org/10.3969/j.issn.0253-9926.2020.05.030CrossRef

32.

Li, L. (2020). Clinical efficacy of metformin combined with Sitagliptin and pioglitazone in the treatment of diabetes mellitus. Journal of Chineses Clinicians, 48(5), 569–571. https://doi.org/10.3969/j.issn.2095-8552.2020.05.019CrossRef

33.

Yanju, L. (2019). Effect of dipeptidyl peptidase-4 inhibitor combined with insulin intensive therapy on blood glucose control and quality of life in newly diagnosed type 2 diabetes patients. Journal of Chronic Pathematology, 20(4), 529–530. https://doi.org/10.16440/j.cnki.1674-8166.20190403.004CrossRef

34.

Wei, L. (2021). Clinical effect and safety analysis of Ligagliptin combined with insulin Detemide in the treatment of type 2 diabetes mellitus. Biabetes New World, 3, 97–99. https://doi.org/10.16658/j.cnki.1672-4062.2021.03.097CrossRef

35.

Xiaoyuan, L. (2020). Effects of dipeptidyl peptidase-4 inhibitors combined with short-term intensive insulin pump therapy on blood glucose control and quality of life in newly diagnosed T2DM patients. Journal of Practical Diabetology, 16(3), 42.

36.

Yuanqiong, P. (2020). Clinical observation of sitagliptin combined with metformin in the treatment of obese type 2 diabetes mellitus. Public Medical Forum Magazine, 24(4), 479–481. https://doi.org/10.19435/j.1672-1721.2020.04.017CrossRef

37.

Fengliang, T. (2022). Efficacy evaluation of sitagliptin combined with Degu insulin in the treatment of type 2 diabetes mellitus. Healthmust-Readmagazine. ;(18):26–27.

38.

Weiwei, W. (2018). Effect of saxagliptin combined with acarbose on blood glucose control and quality of life in elderly patients with newly diagnosed type 2 diabetes mellitus. Contemporary Medicine, 24(8), 105–107. https://doi.org/10.3969/j.issn.1009-4393.2018.08.041CrossRef

39.

Xiaoli, W. (2019). Effects of dipeptidyl peptidase-4 inhibitor combined with protamine biosynthetic human insulin injection (30R) on blood glucose and quality of life in middle-aged and elderly patients with type 2 diabetes mellitus. HENAN MEDICAL RESERACH, 28(24), 4499–4501. https://doi.org/10.3969/j.issn.1004-437X.2019.24.041CrossRef

40.

Hongmei, W. (2018). Effects of Voglibose combined with sitagliptin on FPG and 2hPG levels and quality of life in patients with type 2 diabetes. Capital Food and Medicine, 25(13), 47. https://doi.org/10.3969/j.issn.1005-8257.2018.13.041CrossRef

41.

Zengxun, W. (2019). Efficacy of sitagliptin and insulin glargine injection in elderly patients with T2DM clinical application of integrated traditional Chinese and western medicine. ;19(1):78–79. https://doi.org/10.13638/j.issn.1671-4040.2019.01.038

42.

Yanli, Y., & Wenzheng, Q. (2018). Effect of early intensive insulin pump therapy combined with sitagliptin on serum APN and GLP-1 levels and quality of life in newly diagnosed type 2 diabetes patients. International Medical and Health Review, 24(6), 904–907. https://doi.org/10.3760/cma.j.issn.1007-1245.2018.06.037CrossRef

43.

Huifang, Y. (2018). Effects of saxagliptin combined with insulin on blood glucose control and quality of life in type 2 diabetes mellitus. Inner Mongolia Medicine Journal, 50(5), 513–515. https://doi.org/10.16096/J.cnki.nmgyxzz.2018.50.05.001CrossRef

44.

Hanqi, Z. (2020). Effect analysis of saxagliptin combined with acarbose in treatment of newly diagnosed senile type 2 diabetes mellitus. Health care Guide, 30, 258.

45.

Ting, Z. (2022). Effects of dipeptidyl peptidase-4 inhibitors combined with real-time dynamic insulin pump on blood glucose and quality of life in newly diagnosed type 2 diabetes patients. Self Health Care, 26(17), 160.

46.

Ye, Z. (2021). Application and significance of lipliptin in the treatment of incipient type 2 diabetes mellitus. World Latest Medicine Information, 21(50), 200–201. https://doi.org/10.3969/j.issn.1671-3141.2021.50.099CrossRef

47.

Huiqin, Z., & Xuemei, Z. (2019). To observe the practical value of saxagliptin and acarbose in the treatment of elderly patients with type 2 diabetes. Journal of Clinical Medical, 6(2), 150–152. https://doi.org/10.16281/j.cnki.jocml.2019.02.104CrossRef

48.

Mita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Gosho, M., Ishii, H., Shimomura, I., & Watada, H. (2017). The influence of sitagliptin on treatment-related quality of life in patients with type 2 diabetes Mellitus receiving insulin treatment: A prespecified Sub-analysis. Diabetes Ther Jun, 8(3), 693–704. https://doi.org/10.1007/s13300-017-0267-2CrossRef

49.

Boqi, C. (2022). Clinical effect and adverse reaction of Ligliptin combined with metformin in treatment of newly diagnosed type 2 diabetes mellitus. Diabetic World, 19(1), 85–86.

50.

Lu, Y. (2021). Efficacy of metformin combined with rigliptin in the treatment of type 2 diabetes mellitus. Healthmust-Readmagazine, 5(15), 60.

51.

Qiao, L., & lianshan, Z. (2017). Comparative analysis of efficacy of sitagliptin and acarbose in the treatment of incipient type 2 diabetes. Hebei Medicine, 23(11), 1920–1923.

52.

Hanbing, Y., & Shanshan; C, Huiru, C. (2020). Effect comparison of acarbose and sitagliptin in patients with poor insulin response in T2DM. Mordern Diagnosis Treatment, 31(24), 3910–3912.

53.

Liu, X. (2022). Clinical effect and pharmacological analysis of Vogliptin combined with metformin in patients with type 2 diabetes mellitus. Chinicl Journal of Modern Drug Application, 16(13), 139–142. https://doi.org/10.14164/j.cnki.cn11-5581/r.2022.13.044CrossRef

54.

Ruiping, Z. (2020). Clinical effect of sitagliptin combined with metformin in the treatment of T2DM and its effect on blood glucose level Clinical medicine and practice. ;5(22):45–47. http://doi:10. 19347 / j. cnki. 2096 – 1413. 202022017.

55.

Chen, P. (2018). Effect of acarbose combined with sitagliptin in the treatment of type II diabetes mellitus. Contemporary Medical Symposium, 16(15), 133–134.

56.

Yi, L., & Jianlinh; X, Bilan, Z. (2020). Clinical study of sitagliptin combined with metformin in treatment of type 2 diabetes mellitus. China & Foreign Medical Treatment, 39(33), 106–108. https://doi.org/10.16662/j.cnki.1674-0742.2020.33.106CrossRef

57.

Janssen, M. F., Lubetkin, E. I., Sekhobo, J. P., & Pickard, A. S. (2011). The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus. Diabet Med Apr, 28(4), 395–413. https://doi.org/10.1111/j.1464-5491.2010.03136.xCrossRef

58.

Fayers, P., Aaronson, N. K., Bjordal, K., & Sullivan, M. (1995). EORTC QLQ–C30 scoring manual. European Organisation for Research and Treatment of Cancer.

59.

Zhou, Y., Zhou, R., Li, W., Lin, Y., Yao, J., Chen, J., & Shen, T. (2015). Controlled trial of the effectiveness of community rehabilitation for patients with schizophrenia in Shanghai, China. Shanghai Arch Psychiatry Jun, 25(3), 167–174. https://doi.org/10.11919/j.issn.1002-0829.215026CrossRef

60.

Zhou, Q., Li, X., Zou, F., Wu, L., Chen, H., & Liu, Z. (2011). Effect of systematic self-management education on quality of life, anxiety and depression of patients with type 2 diabetes in communities. Zhong Nan Da Xue Xue Bao Yi Xue Ban Feb, 36(2), 133–137. https://doi.org/10.3969/j.issn.1672-7347.2011.02.007CrossRef

61.

ZhengYi;, F., Baozhen, D., Pei, G., Tanyun, L., Xiaolu, Q., Beiling, W., Junqiao, W., LuHuijuan;, Y., & Yan, Z. (1995). H, Liya. X. evaluation of quality of life in diabetic patients. Chinese Journal of Behavioral Medicine. ;(03):137–139.

62.

Derogatis, L. R., Rickels, K., & Rock, A. F. (1976). The SCL-90 and the MMPI: A step in the validation of a new self-report scale. Br J Psychiatry Mar, 128, 280–289. https://doi.org/10.1192/bjp.128.3.280CrossRef

63.

Ware, J. E. Jr (1976). SF-36 health survey update. Spine (Phila Pa Dec 15 2000;25(24):3130-9. https://doi.org/10.1097/00007632-200012150-00008

64.

Hu, J., Gruber, K. J., & Hsueh, K. H. (2010). Psychometric properties of the Chinese version of the SF-36 in older adults with diabetes in Beijing, China. Diabetes Res Clin Pract Jun, 88(3), 273–281. https://doi.org/10.1016/j.diabres.2010.03.005CrossRef

65.

Fuchigami, A., Shigiyama, F., Kitazawa, T., Okada, Y., Ichijo, T., Higa, M., Hiyoshi, T., Inoue, I., Iso, K., Yoshii, H., Hirose, T., & Kumashiro, N. (2020). Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: A prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol Jan, 7(1), 1. https://doi.org/10.1186/s12933-019-0977-zCrossRef

66.

Deacon, C. F., Mannucci, E., & Ahrén, B. (2012). Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab Aug, 14(8), 762–767. https://doi.org/10.1111/j.1463-1326.2012.01603.xCrossRef

67.

Wang, K., Zhang, Y., Zhao, C., & Jiang, M. (2018). SGLT-2 inhibitors and DPP-4 inhibitors as second-line drugs in patients with type 2 diabetes: A Meta-analysis of Randomized clinical trials. Horm Metab Res Oct, 50(10), 768–777. https://doi.org/10.1055/a-0733-7919CrossRef

68.

Persson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., Bodegard, J., & Birkeland, K. I. (2018). Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab Feb, 20(2), 344–351. https://doi.org/10.1111/dom.13077CrossRef

69.

Ramos, M., Men, P., Wang, X., Ustyugova, A., & Lamotte, M. (2021). Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Eff Resour Alloc Aug, 4(1), 46. https://doi.org/10.1186/s12962-021-00299-zCrossRef

70.

Brazier, J. E., Harper, R., Jones, N. M., O’Cathain, A., Thomas, K. J., Usherwood, T., & Westlake, L. (1992). Validating the SF-36 health survey questionnaire: New outcome measure for primary care. Bmj Jul, 18(6846), 160–164. https://doi.org/10.1136/bmj.305.6846.160CrossRef

71.

Scheen, A. J. (2021). Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes Metab Nov, 47(6), 101275. https://doi.org/10.1016/j.diabet.2021.101275CrossRef

72.

Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med Oct, 3(14), 1317–1326. https://doi.org/10.1056/NEJMoa1307684CrossRef

73.

Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., Zinman, B., Woerle, H. J., Baanstra, D., Pfarr, E., Schnaidt, S., Meinicke, T., George, J. T., von Eynatten, M., & McGuire, D. K. (2019). Effect of Linagliptin vs Placebo on Major Cardiovascular events in adults with type 2 diabetes and High Cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial. Jama Jan, 1(1), 69–79. https://doi.org/10.1001/jama.2018.18269CrossRef

74.

Yu, D. N., Qiu, L., Ning, S. Y., & Guo, L. X. (2020). Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome, 12, 35. https://doi.org/10.1186/s13098-020-00543-1CrossRef

75.

Esposito, K., Chiodini, P., Maiorino, M. I., Bellastella, G., Capuano, A., & Giugliano, D. (2014). Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open Jun, 10(6), e005442. https://doi.org/10.1136/bmjopen-2014-005442CrossRef

76.

Kohsaka, S., Takeda, M., Kidani, Y., & Yajima, T. (2021). Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes. Diabetes Obes Metab Apr, 23(Suppl 2), 28–39. https://doi.org/10.1111/dom.14289CrossRef

77.

Mok, C. H., Kwok, H. H. Y., Ng, C. S., Leung, G. M., & Quan, J. (2021). Health State Utility values for type 2 diabetes and related complications in East and Southeast Asia: A systematic review and Meta-analysis. Value In Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(7), 1059–1067. https://doi.org/10.1016/j.jval.2020.12.019CrossRefPubMed

Titel: The impact of dipeptidyl peptidase 4 inhibitors on health-related quality of life in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Auteurs: Xinyue Zhang
Wai Kei Tong
Qian Xia
Zhijia Tang
Publicatiedatum: 03-08-2024
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 12/2024
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-024-03753-6

Andere artikelen Uitgave 12/2024

Symptom clusters and impact on quality of life in lung cancer patients undergoing chemotherapy

Open Access

Twenty-five years of experience with patient-reported outcome measures in soft-tissue sarcoma patients: a systematic review

Open Access
Review

Evaluating anchor variables and variation in meaningful score differences for PROMIS® Pediatric measures in children and adolescents living with a rheumatic disease

Open Access

Bohn Stafleu van Loghum

The impact of dipeptidyl peptidase 4 inhibitors on health-related quality of life in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Systematic review registration

Andere artikelen Uitgave 12/2024

Symptom clusters and impact on quality of life in lung cancer patients undergoing chemotherapy

Twenty-five years of experience with patient-reported outcome measures in soft-tissue sarcoma patients: a systematic review

Evaluating anchor variables and variation in meaningful score differences for PROMIS® Pediatric measures in children and adolescents living with a rheumatic disease

Screening for depression in patients with epilepsy: same questions but different meaning to different patients

Psychometric properties of patient-reported outcome measures assessing recovery from hand fractures: a systematic review

The association of the comorbidity status of metabolic syndrome and cognitive dysfunction with health-related quality of life

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Systematic review registration

Log in om toegang te krijgen

Symptom clusters and impact on quality of life in lung cancer patients undergoing chemotherapy

Twenty-five years of experience with patient-reported outcome measures in soft-tissue sarcoma patients: a systematic review

Evaluating anchor variables and variation in meaningful score differences for PROMIS® Pediatric measures in children and adolescents living with a rheumatic disease

Screening for depression in patients with epilepsy: same questions but different meaning to different patients

Psychometric properties of patient-reported outcome measures assessing recovery from hand fractures: a systematic review

The association of the comorbidity status of metabolic syndrome and cognitive dysfunction with health-related quality of life